http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, T.H.,Jo, Y.G.,Jiang, H.H.,Lim, S.M.,Youn, Y.S.,Lee, S.,Chen, X.,Byun, Y.,Lee, K.C. Elsevier Science Publishers 2012 Journal of controlled release Vol.162 No.2
Transferrin (Tf) is considered an effective tumor-targeting agent, and PEGylation effectively prolongs in vivo pharmacokinetics by delaying excretion via the renal route. The authors describe the active tumor targeting of long-acting Tf-PEG-TNF-related apoptosis-inducing ligand conjugate (Tf-PEG-TRAIL) for effective cancer therapy. Tf-PEG-TRAIL was prepared using a two-step N-terminal specific PEGylation procedure using different PEGs (Mw: 3.4, 5, 10kDa). Eventually, only 10kDa PEG was linked to Tf and TRAIL because TRAIL (66kDa) and Tf (81kDa) were too large to link to 3.4 and 5kDa PEG. The final conjugate Tf-PEG<SUB>10K</SUB>-TRAIL was successfully purified and characterized by SDS-PAGE, western blotting. To determine the specific binding of Tf-PEG<SUB>10K</SUB>-TRAIL to Tf receptor, competitive receptor binding assays were performed on K 562 cells. The results obtained demonstrate that the affinity of Tf-PEG<SUB>10K</SUB>-TRAIL for Tf receptor is similar to that of native Tf. In contrast, PEG<SUB>10K</SUB>-TRAIL demonstrated no specificity. Biodistribution patterns and antitumor effects were investigated in C57BL6 mice bearing B16F10 murine melanomas and BALB/c athymic mice bearing HCT116. Tumor accumulation of Tf-PEG<SUB>10K</SUB>-TRAIL was 5.2 fold higher (at 2h) than TRAIL, because Tf-PEG<SUB>10K</SUB>-TRAIL has both passive and active tumor targeting ability. Furthermore, the suppression of tumors by Tf-PEG<SUB>10K</SUB>-TRAIL was 3.6 and 1.5 fold those of TRAIL and PEG<SUB>10K</SUB>-TRAIL, respectively. These results suggest that Tf-PEG<SUB>10K</SUB>-TRAIL is a superior pharmacokinetic conjugate that potently targets tumors and that it should be viewed as a potential cancer therapy.